




# Use of the lactic acid bacteria *Streptococcus thermophilus* in inflammaging



## Description

As the world population ages, the prevalence of chronic illness will dramatically increase. Human aging is associated with a chronic, low-grade inflammation, and this phenomenon is called "inflammaging". It represents a significant risk factor for both morbidity and mortality in the elderly people. Indeed, advanced age is characterized by several changes, one of which is the impairment of the homeostasis of intestinal microbiota. Inflammaging is a common trait of several conditions, including sarcopenia.



## Type of expected transfer

Licence option with R&D programme or licence

## Advantages

*Streptococcus thermophilus* has a GRAS and QPS status, the strain has a protective effect against acute and low-grade inflammation disorders in adult mice, it grows in milk and is resistant to lyophilisation

## Possible applications

In inflammaging, limiting muscle mass loss and/or lean body mass loss, weight loss, improving intestinal permeability, limiting colon hypertrophy in humans or animals

## Key words

*Streptococcus thermophilus*, inflammaging, intestinal inflammation, sarcopenia, inflammaging

## TRL Scale



## Development level

Patent n° FR 1856950 « Souche de *Streptococcus thermophilus* CNRZ160 pour le traitement et la prévention de l'inflammation intestinale et des désordres associés, chez un individu »

### Laboratories:

Micalis, Unité de Nutrition Humaine

### Researchers:

Jean-Marc Chatel, Dominique Dardevet

### Contact:

Héloïse Simonson, Licensing Officer Email: [heloise.simonson@inra.fr](mailto:heloise.simonson@inra.fr) Mobile: +33 (0)6 47 05 15 98

Date: 14-05-2019